EnzymeBioSystems (OTCMKTS:ENZB) Files An 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain OfficersItem 5.02 – Departure of Directors or Principal Officers; Election of Directors; Appointment of Principal Officers
On December 27, 2017, the majority shareholders of EnzymeBioSystems (the “Company” or the “Registrant”) voted to realign the Officers in the Company by appointing John Dean Harper to the Board of Directors as the sole Director. Subsequently, the Board of Directors accepted the resignation of Gary Rojewski, in his position as Director and Officer of the Company. Mr. Rojewski tendered his resignation to the Company on December 27, 2017. Mr. Rojewski has not expressed any disagreements with the Company on any matter relating to its operations, policies or practices.
The Board appointed the Company’s Corporate Secretary, John Dean Harper, to the positions of President/CEO and Treasurer. The Board further decided to keep Ashot Marirosyan as Chief Scientific Officer and dissolved the position of Interim Accounting Officer, formerly held by John Dean Harper.
The following table sets forth certain information regarding our current director and executive officer. Set forth below are the names, ages and present principal occupations of our current director and executive officers.
| Name | Age | Position & Offices Held |
| John Dean Harper | Chief Executive Officer/Director | |
| Ashot Martirosyan | Chief Scientific Officer |
All directors hold office until the next annual meeting of stockholders of the Company and until their successors have been elected and qualified. Directors currently receive no fees for services provided in that capacity.
About EnzymeBioSystems (OTCMKTS:ENZB)
EnzymeBioSystems is a development-stage company. The Company researches specialty enzymes and enzyme related products. The Company utilizes enzyme technologies to develop commercial solutions for a range of applications within the specialty chemical industry. It seeks to develop specialty enzymes to eliminate the side effects and toxicity of the new commercially developed products. The Company’s product candidate, Amooranin, is indicated for the treatment of multiple breast cancer. Amooranin is a triterpene acid with a structure isolated from the stem bark of Amoora rohituka, a tropical tree in India. The Company intends to research the study of the use of Amooranin. Specifically, the two areas of this study includes an exam of the in vitro cytotoxicity of Amooranin against hepatocellular carcinoma cells, and investigate the dose responsive antitumor actions of Amooranin against chemically induced hepatic tumorgenesis in rats and dogs.
